临床试验/NCT03516890

NCT03516890已完成不适用

Management of Spontaneous Ruptured Hepatocellular Carcinoma - Partial Hepatectomy and Prognosis: A Retrospective Study

Huazhong University of Science and Technology0 个研究点目标入组 216 人开始时间: 2005年1月1日最近更新: 2018年5月4日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Huazhong University of Science and Technology
入组人数: 216
主要终点: Overall survival of all patients

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

To investigate the best treatment for hepatocellular carcinoma rupture

详细描述

To investigate the best treatment for hepatocellular carcinoma rupture, transcatheter arterial embolization or partial hepatectomy. Furthermore, to discuss the choice of emergency or staged hepatectomy.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 15 Years 至 76 Years（Child, Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Being diagnosed as hepatocellular carcinoma with tumor rupture; with complete data and without loss of follow-up

排除标准

•Without complete data; with loss of follow-up; not hepatocellular carcinoma based on pathological diagnosis

结局指标

主要结局

Overall survival of all patients

时间窗: 5 years

Overall survival difference between the partial hepatectomy group and the non-surgical group

次要结局

Recurrence-free survival of all patients(5 years)
Recurrence-free survival of partial hepatectomy patients(5 years)
Postoperative peritoneal dissemination(5 years)
Overall survival of partial hepatectomy patients(5 years)
Overall survival of staged partial hepatectomy patients(5 years)
Recurrence-free of staged partial hepatectomy patients(5 years)

研究者

发起方

Huazhong University of Science and Technology

申办方类型

Other

责任方

Principal Investigator

主要研究者

Xiaoping Chen

Professor

Huazhong University of Science and Technology

相似试验

已完成

2 期

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma

NCT02513199Icahn School of Medicine at Mount Sinai32

Unknown

2 期

A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.Liver Cancer

NCT00152087St. Joseph's Hospital, Florida25

尚未招募

不适用

Choices of therapeutic strategies for hepatocellular carcinoma (HCC)C22.0Liver cell carcinoma

DRKS00025099Chirurgische Klinik, Universitätsmedizin Mannheim200

Unknown

3 期

Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin AloneCarcinoma, Hepatocellular

NCT00121914Medical University of Vienna120

已完成

不适用

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®Liver TumorsHepatomaNeoplasmsHepatocellular Carcinoma

NCT00877136St. Joseph Hospital of Orange18